Analysts take a look at Horizon Pharma Public Limited Company (NASDAQ:HZNP) having this to say.

April 16, 2018 - By Dolores Ford

Horizon Pharma Public Limited Company (NASDAQ:HZNP) LogoInvestors sentiment increased to 1.04 in Q4 2017. Its up 0.04, from 1 in 2017Q3. It increased, as 30 investors sold Horizon Pharma Public Limited Company shares while 53 reduced holdings. 33 funds opened positions while 53 raised stakes. 128.65 million shares or 2.76% less from 132.29 million shares in 2017Q3 were reported.
Hap Trading Llc holds 52,873 shares or 0.03% of its portfolio. Brandywine Glob Mngmt Lc has 0.36% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 4.16M shares. 104,024 are held by Ubs Asset Management Americas. Parkwood Limited Liability Company has invested 0.2% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Cornerstone Capital Mgmt Hldgs Limited holds 0.04% or 347,700 shares in its portfolio. Rhumbline Advisers reported 181,896 shares or 0.01% of all its holdings. Invesco Ltd has 128,192 shares for 0% of their portfolio. Tekla Capital Management Limited Co has invested 0.09% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Stratos Wealth Ptnrs Limited owns 8,050 shares. 75,800 were accumulated by Prudential Fin. Ghost Tree Ltd Liability Co accumulated 400,000 shares. 32,060 are held by Cim Investment Mangement Incorporated. Zeke Advisors Ltd Liability Corp has 0.02% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 11,433 shares. Martingale Asset Lp holds 100,972 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP).

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 9 analysts covering Horizon Pharma Inc (NASDAQ:HZNP), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Horizon Pharma Inc had 14 analyst reports since October 20, 2017 according to SRatingsIntel. The firm has “Buy” rating by Mizuho given on Friday, January 12. Cowen & Co maintained it with “Buy” rating and $24.0 target in Wednesday, February 28 report. The rating was maintained by UBS with “Buy” on Thursday, November 30. UBS maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Thursday, March 1. UBS has “Buy” rating and $20.0 target. Morgan Stanley maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Friday, March 2. Morgan Stanley has “Equal-Weight” rating and $16 target. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Wednesday, April 11. BMO Capital Markets maintained the shares of HZNP in report on Monday, October 30 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Wednesday, February 28. As per Tuesday, January 30, the company rating was maintained by Piper Jaffray. The rating was maintained by Stifel Nicolaus on Friday, October 20 with “Buy”. Below is a list of Horizon Pharma Public Limited Company (NASDAQ:HZNP) latest ratings and price target changes.

11/04/2018 Broker: Mizuho Rating: Buy New Target: $18.0000 Maintain
02/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $14 New Target: $16 Maintain
28/02/2018 Broker: Cowen & Co Rating: Buy New Target: $24.0 Maintain
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $22.0 Maintain
01/03/2018 Broker: UBS Rating: Buy New Target: $20.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
30/11/2017 Broker: UBS Rating: Buy New Target: $20.0 Maintain
10/11/2017 Broker: Cowen & Co Rating: Buy New Target: $22.0 Maintain

The stock decreased 1.75% or $0.24 during the last trading session, reaching $13.46. About 272,359 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 6.20% since April 16, 2017 and is downtrending. It has underperformed by 17.75% the S&P500.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.22 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts